After Oppenheimer and Maxim Group gave ADMA Biologics (NASDAQ: ADMA) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Keay Nakae reiterated a Buy rating on ADMA Biologics today and set a price target of $8.50. The company’s shares opened today at $3.93.
According to TipRanks.com, Nakae has 0 stars on 0-5 star ranking scale with an average return of -8.7% and a 35.3% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Emergent Biosolutions.
ADMA Biologics has an analyst consensus of Strong Buy, with a price target consensus of $11.25, which is a 186.3% upside from current levels. In a report released today, Oppenheimer also assigned a Buy rating to the stock with a $14 price target.
Based on ADMA Biologics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.14 million. In comparison, last year the company had a GAAP net loss of $12.98 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.